Mabwell to Present Latest Clinical Data for ADC 9MW2821 at 2026 ASCO Annual Meeting

Stock News05-21

Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it will present clinical data for its targeted Nectin-4 ADC novel drug, 9MW2821 (Bulumtatug Fuvedotin, BFv), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 29 to June 2, 2026. The presentation will include an oral report on Ib/II phase clinical study data for 9MW2821 in combination with toripalimab for locally advanced or metastatic urothelial carcinoma (la/mUC). Additionally, a poster presentation will feature II phase clinical study data for 9MW2821 combined with toripalimab for perioperative muscle-invasive bladder cancer (MIBC). 9MW2821 is Mabwell's first site-specific conjugated ADC drug targeting Nectin-4, developed using the company's ADC drug development platform. It employs proprietary conjugation technology linkers and an optimized ADC conjugation process to achieve site-specific antibody modification. After administration, 9MW2821 binds to Nectin-4 on the surface of tumor cells and enters the cells, where enzymatic cleavage directs the release of cytotoxic agents, enabling precise targeting and destruction of tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187250283?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 17:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187250283","market":"sh","top_or_hot":-1,"title":"Mabwell to Present Latest Clinical Data for ADC 9MW2821 at 2026 ASCO Annual Meeting","media":"Stock News","content":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it will present clinical data for its targeted Nectin-4 ADC novel drug, 9MW2821 (Bulumtatug Fuvedotin, BFv), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 29 to June 2, 2026. The presentation will include an oral report on Ib/II phase clinical study data for 9MW2821 in combination with toripalimab for locally advanced or metastatic urothelial carcinoma (la/mUC). Additionally, a poster presentation will feature II phase clinical study data for 9MW2821 combined with toripalimab for perioperative muscle-invasive bladder cancer (MIBC). 9MW2821 is Mabwell's first site-specific conjugated ADC drug targeting Nectin-4, developed using the company's ADC drug development platform. It employs proprietary conjugation technology linkers and an optimized ADC conjugation process to achieve site-specific antibody modification. After administration, 9MW2821 binds to Nectin-4 on the surface of tumor cells and enters the cells, where enzymatic cleavage directs the release of cytotoxic agents, enabling precise targeting and destruction of tumors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabwell to Present Latest Clinical Data for ADC 9MW2821 at 2026 ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabwell to Present Latest Clinical Data for ADC 9MW2821 at 2026 ASCO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-21 17:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it will present clinical data for its targeted Nectin-4 ADC novel drug, 9MW2821 (Bulumtatug Fuvedotin, BFv), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 29 to June 2, 2026. The presentation will include an oral report on Ib/II phase clinical study data for 9MW2821 in combination with toripalimab for locally advanced or metastatic urothelial carcinoma (la/mUC). Additionally, a poster presentation will feature II phase clinical study data for 9MW2821 combined with toripalimab for perioperative muscle-invasive bladder cancer (MIBC). 9MW2821 is Mabwell's first site-specific conjugated ADC drug targeting Nectin-4, developed using the company's ADC drug development platform. It employs proprietary conjugation technology linkers and an optimized ADC conjugation process to achieve site-specific antibody modification. After administration, 9MW2821 binds to Nectin-4 on the surface of tumor cells and enters the cells, where enzymatic cleavage directs the release of cytotoxic agents, enabling precise targeting and destruction of tumors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688062","symbol_name":"迈威生物-U","start_time":0,"source_url":"","article_id":"1187250283","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187250283","pubTimestamp":1779355318,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it will present clinical data for its targeted Nectin-4 ADC novel drug, 9MW2821 (Bulumtatug Fuvedotin, BFv), at the 2026 American Society of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688062":"迈威生物-U","BK0239":"医药制造","BK1161":"生物科技","02493":"迈威生物-B"},"translate_title":"Mabwell将在2026年ASCO年会上展示ADC 9MW2821的最新临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688062":1,"02493":1},"content_text":"Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it will present clinical data for its targeted Nectin-4 ADC novel drug, 9MW2821 (Bulumtatug Fuvedotin, BFv), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 29 to June 2, 2026. The presentation will include an oral report on Ib/II phase clinical study data for 9MW2821 in combination with toripalimab for locally advanced or metastatic urothelial carcinoma (la/mUC). Additionally, a poster presentation will feature II phase clinical study data for 9MW2821 combined with toripalimab for perioperative muscle-invasive bladder cancer (MIBC). 9MW2821 is Mabwell's first site-specific conjugated ADC drug targeting Nectin-4, developed using the company's ADC drug development platform. It employs proprietary conjugation technology linkers and an optimized ADC conjugation process to achieve site-specific antibody modification. After administration, 9MW2821 binds to Nectin-4 on the surface of tumor cells and enters the cells, where enzymatic cleavage directs the release of cytotoxic agents, enabling precise targeting and destruction of tumors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187250283","isCrawlerRequest":true}